Tagged with Cell & Gene,

Chinese Cell & Gene Companies to Follow

China Chinese Cell & Gene Companies to Follow

China Due in part to an increasingly encouraging regulatory environment, China continues to strive for progress in cell and gene therapies (CGT). In fact, according to a 2021 Nature study, CAR T-cell therapy clinical trials in China have accounted for over 50% of registered CGT studies worldwide. Currently, over 200 CAR-T…

Jean-Christophe Hyvert – President Biologics and Cell & Gene, Lonza

Switzerland Jean-Christophe Hyvert – President Biologics and Cell & Gene, Lonza

Switzerland Swiss-based Lonza has consolidated as a titan in the CDMO industry with annual revenues of around CHF 5.9bn for 2020. Its president for the Biologics and Cell & Gene divisions, Jean-Christophe Hyvert, comments on the restructuring of the company, why the divesture of the specialty ingredients division makes sense in…

Novartis: CAR-T’s Journey to Market in Europe

Cell & Gene Therapy Novartis: CAR-T’s Journey to Market in Europe

Cell & Gene Therapy Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene therapy, spoke to PharmaBoardroom about the pioneering product’s journey to market, what has been learnt along the way, and how his team has worked to assuage concerns…

Emanuele Ostuni – Head of Europe, Cell & Gene Therapy, Novartis Oncology

Cell & Gene Therapy Emanuele Ostuni – Head of Europe, Cell & Gene Therapy, Novartis Oncology

Cell & Gene Therapy Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T therapy to Europe, the work still to be done to get this product to more patients who need it across the continent, and the future of cell and…

Cell & Gene Therapy Manufacturing: Critical Challenges, Innovative Responses

Cell & Gene Therapy Cell & Gene Therapy Manufacturing: Critical Challenges, Innovative Responses

Cell & Gene Therapy Deloitte’s Omkar Kawalekar, Hussain Mooraj, and Amit Agarwal examine the evolution and future of cell and gene therapy manufacturing and the areas in which biopharma firms need to invest in order to succeed in this emergent field. Cell and gene therapies (CGT) are the next evolution of personalized health…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page